These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15841327)

  • 1. Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1.
    Setyono-Han B; Stürzebecher J; Schmalix WA; Muehlenweg B; Sieuwerts AM; Timmermans M; Magdolen V; Schmitt M; Klijn JG; Foekens JA
    Thromb Haemost; 2005 Apr; 93(4):779-86. PubMed ID: 15841327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system.
    Ertongur S; Lang S; Mack B; Wosikowski K; Muehlenweg B; Gires O
    Int J Cancer; 2004 Jul; 110(6):815-24. PubMed ID: 15170662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread.
    Sato S; Kopitz C; Schmalix WA; Muehlenweg B; Kessler H; Schmitt M; Krüger A; Magdolen V
    FEBS Lett; 2002 Sep; 528(1-3):212-6. PubMed ID: 12297307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.
    Xing RH; Mazar A; Henkin J; Rabbani SA
    Cancer Res; 1997 Aug; 57(16):3585-93. PubMed ID: 9270032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
    Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
    Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
    Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis.
    Zengel P; Ramp D; Mack B; Zahler S; Berghaus A; Muehlenweg B; Gires O; Schmitz S
    BMC Cancer; 2010 Mar; 10():92. PubMed ID: 20222943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours.
    Muehlenweg B; Sperl S; Magdolen V; Schmitt M; Harbeck N
    Expert Opin Biol Ther; 2001 Jul; 1(4):683-91. PubMed ID: 11727504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy?
    Fazioli F; Blasi F
    Trends Pharmacol Sci; 1994 Jan; 15(1):25-9. PubMed ID: 8140655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
    Mahanivong C; Yu J; Huang S
    Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
    Kenichi M; Masanobu M; Takehiko K; Shoko T; Akira F; Katsushige A; Takashi H; Yoshiyuki O; Shigeru K
    J Lab Clin Med; 2004 Aug; 144(2):69-77. PubMed ID: 15322501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties.
    Joossens J; Ali OM; El-Sayed I; Surpateanu G; Van der Veken P; Lambeir AM; Setyono-Han B; Foekens JA; Schneider A; Schmalix W; Haemers A; Augustyns K
    J Med Chem; 2007 Dec; 50(26):6638-46. PubMed ID: 18052026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.
    Choong PF; Nadesapillai AP
    Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S46-58. PubMed ID: 14600592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
    Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
    Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experimental study of anti-metastasis effect of urokinase amino-terminal fragment gene on human breast cancer cells].
    Zhu F; Xing G; He F
    Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):115-7. PubMed ID: 11783013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
    McGowen R; Biliran H; Sager R; Sheng S
    Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain.
    Kim KS; Hong YK; Lee Y; Shin JY; Chang SI; Chung SI; Joe Y
    Exp Mol Med; 2003 Dec; 35(6):578-85. PubMed ID: 14749538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptides and small molecules targeting the plasminogen activation system: towards prophylactic anti-metastasis drugs for breast cancer.
    Tyndall JD; Kelso MJ; Clingan P; Ranson M
    Recent Pat Anticancer Drug Discov; 2008 Jan; 3(1):1-13. PubMed ID: 18289119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.